These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15056493)

  • 21. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S; Velazquez F; Wu W; Blackman M; Madison V; Njoroge FG
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2151-5. PubMed ID: 20226659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase.
    Liu D; Wang YS; Gesell JJ; Wyss DF
    J Mol Biol; 2001 Nov; 314(3):543-61. PubMed ID: 11846566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
    De Francesco R; Pessi A; Steinkühler C
    Antivir Ther; 1998; 3(Suppl 3):99-109. PubMed ID: 10726060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
    J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): model compounds towards small molecule inhibitors.
    Oscarsson K; Poliakov A; Oscarson S; Danielson UH; Hallberg A; Samuelsson B
    Bioorg Med Chem; 2003 Jul; 11(13):2955-63. PubMed ID: 12788365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.
    Zhang R; Durkin JP; Windsor WT
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1005-8. PubMed ID: 11909704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
    Naud J; Lemke C; Goudreau N; Beaulieu E; White PD; Llinàs-Brunet M; Forgione P
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3400-4. PubMed ID: 18448339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
    Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease.
    Kirschberg TA; Squires NH; Yang H; Corsa AC; Tian Y; Tirunagari N; Sheng XC; Kim CU
    Bioorg Med Chem Lett; 2014 Feb; 24(3):969-72. PubMed ID: 24405705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease.
    Zhang X; Schmitt AC; Jiang W; Wasserman Z; Decicco CP
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1157-60. PubMed ID: 12643933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro.
    Shi F; Zhang Y; Xu W
    Bioorg Med Chem; 2015 Sep; 23(17):5539-45. PubMed ID: 26238980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX; Moya A; Gonzàlez-Candelas F
    Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative analysis of the substrate permissiveness of HCV and GBV-B NS3/4A proteases reveals genetic evidence for an interaction with NS4B protein during genome replication.
    Benureau Y; Warter L; Malcolm BA; Martin A
    Virology; 2010 Oct; 406(2):228-40. PubMed ID: 20701941
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease.
    Andrews DM; Carey SJ; Chaignot H; Coomber BA; Gray NM; Hind SL; Jones PS; Mills G; Robinson JE; Slater MJ
    Org Lett; 2002 Dec; 4(25):4475-8. PubMed ID: 12465916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serpin mechanism of hepatitis C virus nonstructural 3 (NS3) protease inhibition: induced fit as a mechanism for narrow specificity.
    Richer MJ; Juliano L; Hashimoto C; Jean F
    J Biol Chem; 2004 Mar; 279(11):10222-7. PubMed ID: 14701815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease.
    Tomei L; Failla C; Vitale RL; Bianchi E; De Francesco R
    J Gen Virol; 1996 May; 77 ( Pt 5)():1065-70. PubMed ID: 8609472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.